These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 21628718)

  • 1. Safety evaluation of chronic intrathecal administration of idursulfase-IT in cynomolgus monkeys.
    Felice BR; Wright TL; Boyd RB; Butt MT; Pfeifer RW; Pan J; Ruiz JA; Heartlein MW; Calias P
    Toxicol Pathol; 2011 Aug; 39(5):879-92. PubMed ID: 21628718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and bioavailability of a therapeutic enzyme (idursulfase) in cynomolgus monkeys after intrathecal and intravenous administration.
    Xie H; Chung JK; Mascelli MA; McCauley TG
    PLoS One; 2015; 10(4):e0122453. PubMed ID: 25836678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biodistribution of Idursulfase Formulated for Intrathecal Use (Idursulfase-IT) in Cynomolgus Monkeys after Intrathecal Lumbar Administration.
    Chung JK; Brown E; Crooker B; Palmieri KJ; McCauley TG
    PLoS One; 2016; 11(10):e0164765. PubMed ID: 27764180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS).
    Alcalde-Martín C; Muro-Tudelilla JM; Cancho-Candela R; Gutiérrez-Solana LG; Pintos-Morell G; Martí-Herrero M; Munguira-Aguado P; Galán-Gómez E
    Eur J Med Genet; 2010; 53(6):371-7. PubMed ID: 20709629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome).
    Muenzer J; Gucsavas-Calikoglu M; McCandless SE; Schuetz TJ; Kimura A
    Mol Genet Metab; 2007 Mar; 90(3):329-37. PubMed ID: 17185020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
    da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
    Cochrane Database Syst Rev; 2011 Nov; (11):CD008185. PubMed ID: 22071845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II.
    Muenzer J; Hendriksz CJ; Fan Z; Vijayaraghavan S; Perry V; Santra S; Solanki GA; Mascelli MA; Pan L; Wang N; Sciarappa K; Barbier AJ
    Genet Med; 2016 Jan; 18(1):73-81. PubMed ID: 25834948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
    da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
    Cochrane Database Syst Rev; 2014 Jan; (1):CD008185. PubMed ID: 24399699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
    da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD008185. PubMed ID: 26845288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder.
    Calias P; Papisov M; Pan J; Savioli N; Belov V; Huang Y; Lotterhand J; Alessandrini M; Liu N; Fischman AJ; Powell JL; Heartlein MW
    PLoS One; 2012; 7(1):e30341. PubMed ID: 22279584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II.
    Garcia AR; DaCosta JM; Pan J; Muenzer J; Lamsa JC
    Mol Genet Metab; 2007 Jun; 91(2):183-90. PubMed ID: 17459751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of enzyme replacement therapy with idursulfase beta in children aged younger than 6 years with Hunter syndrome.
    Sohn YB; Cho SY; Lee J; Kwun Y; Huh R; Jin DK
    Mol Genet Metab; 2015 Feb; 114(2):156-60. PubMed ID: 25219292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I.
    Kakkis E; McEntee M; Vogler C; Le S; Levy B; Belichenko P; Mobley W; Dickson P; Hanson S; Passage M
    Mol Genet Metab; 2004; 83(1-2):163-74. PubMed ID: 15464431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical study of enzyme replacement therapy with idursulfase].
    Gutiérrez-Solana LG
    Rev Neurol; 2007 Feb; 44 Suppl 1():S7-S11. PubMed ID: 17345556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase.
    Barbier AJ; Bielefeld B; Whiteman DA; Natarajan M; Pano A; Amato DA
    Mol Genet Metab; 2013 Nov; 110(3):303-10. PubMed ID: 23988379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome.
    Kim J; Park MR; Kim DS; Lee JO; Maeng SH; Cho SY; Han Y; Ahn K; Jin DK
    Allergy; 2013 Jun; 68(6):796-802. PubMed ID: 23621439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Early response to idursulfase in a 31-year old male patient with Hunter syndrome].
    Pérez-Calvo J; Bergua Sanclemente I; López Moreno MJ; Torralba Cabeza MÁ; Amores Arriaga B
    Rev Clin Esp; 2011; 211(7):e42-5. PubMed ID: 21524741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II.
    Muenzer J; Burton BK; Harmatz P; Gutiérrez-Solana LG; Ruiz-Garcia M; Jones SA; Guffon N; Inbar-Feigenberg M; Bratkovic D; Hale M; Wu Y; Yee KS; Whiteman DAH; Alexanderian D;
    Mol Genet Metab; 2022; 137(1-2):92-103. PubMed ID: 35961250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of idursulfase in the treatment of mucopolysaccharidosis II (Hunter syndrome): a post-marketing study in Japan.
    Ueda K; Hokugo J
    Expert Opin Drug Saf; 2020 Jul; 19(7):891-901. PubMed ID: 32342708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.